Northern Trust’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.15M | Buy |
2,955,282
+1,669,580
| +130% | +$3.67M | ﹤0.01% | 2509 |
|
|
2026
Q1 | $3.14M | Buy |
1,285,702
+87,235
| +7% | +$175K | ﹤0.01% | 2717 |
|
|
2025
Q4 | $1.64M | Sell |
1,198,467
-81,161
| -6% | -$107K | ﹤0.01% | 3110 |
|
|
2025
Q3 | $1.59M | Buy |
1,279,628
+5,336
| +0.4% | +$6.36K | ﹤0.01% | 3159 |
|
|
2025
Q2 | $1.44M | Buy |
1,274,292
+79,882
| +7% | +$106K | ﹤0.01% | 3187 |
|
|
2025
Q1 | $1.74M | Sell |
1,194,410
-110,822
| -8% | -$209K | ﹤0.01% | 2991 |
|
|
2024
Q4 | $2.78M | Buy |
1,305,232
+56,693
| +5% | +$140K | ﹤0.01% | 2834 |
|
|
2024
Q3 | $3.5M | Buy |
1,248,539
+210,434
| +20% | +$561K | ﹤0.01% | 2686 |
|
|
2024
Q2 | $2.42M | Buy |
1,038,105
+67,038
| +7% | +$198K | ﹤0.01% | 2794 |
|
|
2024
Q1 | $4.34M | Sell |
971,067
-43,278
| -4% | -$181K | ﹤0.01% | 2563 |
|
|
2023
Q4 | $3.26M | Buy |
1,014,345
+153,818
| +18% | +$436K | ﹤0.01% | 2720 |
|
|
2023
Q3 | $2.73M | Sell |
860,527
-1,979
| -0.2% | -$8.67K | ﹤0.01% | 2768 |
|
|
2023
Q2 | $4.29M | Buy |
862,506
+63,333
| +8% | +$343K | ﹤0.01% | 2584 |
|
|
2023
Q1 | $3.95M | Sell |
799,173
-31,231
| -4% | -$200K | ﹤0.01% | 2599 |
|
|
2022
Q4 | $5.22M | Sell |
830,404
-335,206
| -29% | -$3.1M | ﹤0.01% | 2458 |
|
|
2022
Q3 | $12.6M | Buy |
1,165,610
+413,301
| +55% | +$5.62M | ﹤0.01% | 1823 |
|
|
2022
Q2 | $8.58M | Buy |
752,309
+53,229
| +8% | +$473K | ﹤0.01% | 2141 |
|
|
2022
Q1 | $6.37M | Sell |
699,080
-25,637
| -4% | -$267K | ﹤0.01% | 2437 |
|
|
2021
Q4 | $10.8M | Buy |
724,717
+11,215
| +2% | +$198K | ﹤0.01% | 2179 |
|
|
2021
Q3 | $18.3M | Sell |
713,502
-21,592
| -3% | -$513K | ﹤0.01% | 1862 |
|
|
2021
Q2 | $19.2M | Buy |
735,094
+86,630
| +13% | +$2.47M | ﹤0.01% | 1916 |
|
|
2021
Q1 | $22.9M | Sell |
648,464
-20,143
| -3% | -$679K | ﹤0.01% | 1717 |
|
|
2020
Q4 | $16.9M | Sell |
668,607
-12,980
| -2% | -$423K | ﹤0.01% | 1915 |
|
|
2020
Q3 | $25.7M | Buy |
681,587
+8,969
| +1% | +$338K | 0.01% | 1433 |
|
|
2020
Q2 | $28.8M | Buy |
672,618
+154,124
| +30% | +$5.57M | 0.01% | 1320 |
|
|
2020
Q1 | $10.1M | Buy |
518,494
+6,479
| +1% | +$154K | ﹤0.01% | 1864 |
|
|
2019
Q4 | $13.3M | Sell |
512,015
-15,965
| -3% | -$440K | ﹤0.01% | 1993 |
|
|
2019
Q3 | $14.4M | Buy |
527,980
+216,959
| +70% | +$6.18M | ﹤0.01% | 1913 |
|
|
2019
Q2 | $8.35M | Buy |
311,021
+20,971
| +7% | +$584K | ﹤0.01% | 2262 |
|
|
2019
Q1 | $8.38M | Buy |
290,050
+3,810
| +1% | +$111K | ﹤0.01% | 2260 |
|
|
2018
Q4 | $7.71M | Buy |
+286,240
| New | +$7.6M | ﹤0.01% | 2234 |
|
Other funds holding ALLO
P
FLSM
TGA
SCM
Northern Trust's ALLO Position: Q2 2026 in Review
Northern Trust increased its Allogene Therapeutics (ALLO) stake by 130% in Q2 2026, buying an estimated $3.67M and bringing the position to 2,955,282 shares worth $6.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2509.
Northern Trust first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $28.8M in Q2 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.
- Northern Trust held 2,955,282 shares of Allogene Therapeutics worth $6.15M as of Q2 2026.
- Northern Trust bought 1,669,580 Allogene Therapeutics shares in Q2 2026, an estimated $3.67M.
- Allogene Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2509 holding.
- Northern Trust first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
- Northern Trust's Allogene Therapeutics position peaked at $28.8M in Q2 2020.
- 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.